Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Erasca, Inc. (ERAS)
Company Research
Source: GlobeNewswire
Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will provide Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015. Under the terms of the ERAS-0015 license agreement, Erasca exercised its option to convert its territory to worldwide and is obligated to make a one-time payment to Joyo based on the stage of Joy
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/16/26 - Form 144
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- ERAS's page on the SEC website